# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
EF Hutton analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $5 price target.
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical TrialNEW YORK, Sept. 5, ...